Picture from Wang H et al. (2005) Mol Biol Cell "The terminal phase of cytokinesis in the Caenorhabditis elegans early embryo ...."

Figure 4. Gal-T2 localization and detection in C. elegans. (A) Anti-Gal-T2 scFv antibody staining alone (top) or with DAPI nuclear counterstain (bottom) in an eight-cell embryo. (B) High magnification of Golgi apparatus staining and nuclei from embryo in A. (C) Anti-Gal-T2 scFv antibody staining in a 28-cell embryo shows perinuclear staining pattern. (D) GFP fluorescence staining and DIC of intestinal cells from transgenic animals expressing a fusion of the N terminus and stem of Gal-T2 (1-60 aa) to a GFP reporter. Two nuclei are present in the GFP-positive cell. The GFP fluorescence surrounds the left nucleus and forms a patch next to the right nucleus. The nuclei themselves do not exhibit a GFP signal. (E) Structure and design of the wild-type Gal-T2 gene and the Gal-T2 stem::GFP reporter. GFP is fused to amino acid codon 60 in the second exon, such that GFP replaces the C-terminal catalytic domain of Gal-T2. (F) Western blot detection of Gal-T2 with anti-Gal-T2 scFv antibody. Lanes 1 and 2, 50 and 20 ng of recombinant Gal-T2, lacking the N-terminal transmembrane domain. In place of the transmembrane domain, a 38-amino acid purification tag is genetically fused to the stem and catalytic domain of Gal-T2 (see Materials and Methods for details). Lanes 3 and 4, 40 and 15 ng of recombinant Gal-T2 after peptide:N-glycanase and O-glycanase treatment.

Picture from Wang H et al. (2005) Mol Biol Cell "The terminal phase of cytokinesis in the Caenorhabditis elegans early embryo ...."

Figure 4. Gal-T2 localization and detection in C. elegans. (A) Anti-Gal-T2 scFv antibody staining alone (top) or with DAPI nuclear counterstain (bottom) in an eight-cell embryo. (B) High magnification of Golgi apparatus staining and nuclei from embryo in A. (C) Anti-Gal-T2 scFv antibody staining in a 28-cell embryo shows perinuclear staining pattern. (D) GFP fluorescence staining and DIC of intestinal cells from transgenic animals expressing a fusion of the N terminus and stem of Gal-T2 (1-60 aa) to a GFP reporter. Two nuclei are present in the GFP-positive cell. The GFP fluorescence surrounds the left nucleus and forms a patch next to the right nucleus. The nuclei themselves do not exhibit a GFP signal. (E) Structure and design of the wild-type Gal-T2 gene and the Gal-T2 stem::GFP reporter. GFP is fused to amino acid codon 60 in the second exon, such that GFP replaces the C-terminal catalytic domain of Gal-T2. (F) Western blot detection of Gal-T2 with anti-Gal-T2 scFv antibody. Lanes 1 and 2, 50 and 20 ng of recombinant Gal-T2, lacking the N-terminal transmembrane domain. In place of the transmembrane domain, a 38-amino acid purification tag is genetically fused to the stem and catalytic domain of Gal-T2 (see Materials and Methods for details). Lanes 3 and 4, 40 and 15 ng of recombinant Gal-T2 after peptide:N-glycanase and O-glycanase treatment.

Picture from Petalcorin MIR et al. (2005) Gene "The fmo genes of Caenorhabditis elegans and C. briggsae: characterisation, gene ...."

h-Gal expression for fmo-2 from LacZ transcriptional fusion reporters in adult hermaphrodites (200 magnification).

Picture from Petalcorin MIR et al. (2005) Gene "The fmo genes of Caenorhabditis elegans and C. briggsae: characterisation, gene ...."

h-Gal expression for fmo-5 from LacZ transcriptional fusion reporters in adult hermaphrodites (200 magnification).

Picture from Petalcorin MIR et al. (2005) Gene "The fmo genes of Caenorhabditis elegans and C. briggsae: characterisation, gene ...."

h-Gal expression for fmo-1 from LacZ transcriptional fusion reporters in adult hermaphrodites (200 magnification).

Picture from Petalcorin MIR et al. (2005) Gene "The fmo genes of Caenorhabditis elegans and C. briggsae: characterisation, gene ...."

h-Gal expression for fmo-4 from LacZ transcriptional fusion reporters in adult hermaphrodites (200 magnification).

Picture from Petalcorin MIR et al. (2005) Gene "The fmo genes of Caenorhabditis elegans and C. briggsae: characterisation, gene ...."

h-Gal expression for fmo-3 from LacZ transcriptional fusion reporters in adult hermaphrodites (200 magnification).

Picture from Power KM et al. (2024) MicroPubl Biol "osm-5p- driven fluorophores are differentially expressed in ...."

Figure 1. osm-5p-driven soluble GFP differs in brightness in ccpp-1Δ and nekl-4Δ mutant ciliated neurons: a. Widefield images of soluble osm-5p::GFP in the phasmid soma, sum intensity projections. Scale bar = 5 µm. b. Quantification of mean fluorescence intensity and integrated density of osm-5p::GFP fluorescence in the phasmid soma. au = arbitrary unit. Mean ± SEM; * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤ 0.001, **** indicates p ≤ 0.0001 by Kruskal-Wallis one-way ANOVA with post hoc Dunn's correction for multiple comparisons. n is indicated above each genotype. Black indicates significance relative to WT, red indicates significance relative to ccpp-1Δ.

Picture from Pohl F et al. (2024) MicroPubl Biol "Pharmacological inhibition of acetylcholinesterase improves the locomotion ...."

Figure 1. Pharmacological acetylcholinesterase inhibition ameliorates mutant ATXN3-medited motor defects in a SCA3 C elegans model:A: neostigmine (0.01-10.0 mM) shows no major toxic effects in C. elegans. Toxicity was assessed using the food clearance assay. The optical density of the OP50 suspension with neostigmne-treated animals (N2) at the concentrations depicted, was measured daily. The mean OD was calculated for each day from five samples and plotted over time. Control DMSO (1%) corresponds to drug vehicle and DMSO at 5% was used as positive (toxic compound) control. B: Locomotion defective behaviour of AT3q130 animals, comparison between treated (neostigmine 0.01-10 mM) and untreated animals in comparison to wild type (N2) and AT3q14 controls. Statistical significant difference determined using One-way ANOVA and Bonferroni's multiple comparison analysis compared to AT3q130 control: ***p≤0.001 (decreased motility); *p≤0.05, ***p≤0.001; n=5 C: Locomotion defective behaviour of AT3q130 animals, comparison between treated (neostigmine 0.1-10 µM) and untreated animals in comparison to wild type (N2) and AT3q14 controls. Statistical significant difference determined using One-way ANOVA and Bonferroni's multiple comparison analysis compared to AT3q130 control: ***p≤0.001, **p≤0.01, n=5 D: Locomotion defective behaviour of AT3q130 animals compared to double mutant AT3q130; ace-1 and WT and ace-1 control. Statistical significant difference determined using One-way ANOVA and Bonferroni's multiple comparison analysis: ***p≤0.001, ns-not significant; n=5 E: Locomotion defective behaviour of AT3q130 animals compared to double mutant AT3q130; ace-2 and WT and ace-2 control. Statistical significant difference determined using One-way ANOVA and Bonferroni's multiple comparison analysis: *p≤0.05, **p≤0.01, ns-not significant; n=4

Picture from Henderson ST et al. (1994) Development "lag-2 may encode a signaling ligand for the GLP-1 and LIN-12 receptors of C. ...."

Figure 6. Distribution of LAG-2::β-gal and GLP-1 in adult germline.(A) Schematic representation of distal region of adult germline, showing DTC on left. DTC nucleus shown as open circle, mitotic germ nuclei shown as black circles. Thin lines represent cell membranes, mitotic germ line is a syncytium. Scale bar, 20 µm. (B-D) Confocal images of dissected germlines that have been double stained with both anti-β-galactosidase (red) and anti-GLP-1 (green)antibodies. (B) GLP-1 is present in germline membranes. See Crittenden et al. (accompanying paper) to see definitively that the DTC does not contain GLP-1. (C) The LAG-2::β-gal fusion protein is present in the DTC and also near the center of the germline. (D) Simultaneous detection of anti-GLP-1 and anti-β-gal using merged fluorescein and rhodamine confocal image. Note co-localization of GLP-1 staining and β-gal staining within membranes of the germline.